870709-87-8Relevant articles and documents
Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11β-hydroxysteroid dehydrogenase type 1 inhibitors: Reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model
Fotsch, Christopher,Bartberger, Michael D.,Bercot, Eric A.,Chen, Michelle,Cupples, Rod,Emery, Maury,Fretland, Jenne,Guram, Anil,Hale, Clarence,Han, Nianhe,Hickman, Dean,Hungate, Randall W.,Hayashi, Michael,Komorowski, Renee,Liu, Qingyian,Matsumoto, Guy,St. Jean Jr., David J.,Ursu, Stefania,Véniant, Murielle,Xu, Guifen,Ye, Qiuping,Yuan, Chester,Zhang, Jiandong,Zhang, Xiping,Tu, Hua,Wang, Minghan
experimental part, p. 7953 - 7967 (2009/12/07)
A series of compounds containing the 2-amino-1,3-thiazol-4(5H)-one core were found to be potent inhibitors of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). One of our lead compounds from this series activated the human nuclear xenobiotic
INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1
-
Page/Page column 177, (2008/06/13)
The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme an